Trial Profile
Multicenter Retrospective Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Cobicistat/darunavir (Primary) ; Dolutegravir; Rilpivirine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms CoDAR
- 27 Jan 2021 Results (n=725) assessing changes in creatinine estimated glomerular filtration rate, published in the Journal of Antimicrobial Chemotherapy.
- 05 Oct 2019 Results determining the characteristics of darunavir/cobicistat use in HIV-infected adults in Spain published in the Journal of Antimicrobial Chemotherapy
- 24 Jun 2019 Results published in the Journal of Antimicrobial Chemotherapy